Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)

Inclusion Criteria: * If of reproductive potential, must agree to remain abstinent or use (or have their partner use) 2 acceptable methods of birth control for the duration of the study * Diagnosed with Heterozygous Familial Hypercholesterolemia (HeFH) * Have been treated with an optimal dose of statin for at least 6 weeks Exclusion Criteria: * Received treatment with low-density lipoprotein (LDL) apheresis within 4 weeks of screening or expect to undergo treatment with LDL apheresis during the course of the study * Homozygous familial hypercholesterolemia * Severe chronic heart failure * Uncontrolled hypertension * Uncontrolled cardiac arrhythmias, myocardial infarction (MI), percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), unstable angina, or stroke within 3 months * Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins * Active or chronic hepatobiliary, hepatic, or gall bladder disease * Pregnant or breast-feeding, or plans to become pregnant during the study or within 2 years after stopping study medication * History of ileal bypass, gastric bypass, or other significant condition associated with malabsorption * Human immunodeficiency virus (HIV) positive * History of malignancy ≤5 years * Donated blood products or has had phlebotomy of \>300 mL within 8 weeks or intends to donate 250 mL of blood products or receive blood products within the projected duration of the study * Currently taking medications…